Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report

Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report

Most cases of acute promyelocytic leukemia (APL) are driven by the PML::RARA fusion gene, which is sensitive to differentiation induction therapy comprising of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Treatment with ATRA plus ATO has achieved remarkable clinical outcome in patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Xianfeng Ouyang, Jianguo Yan, Su Hu, Wenfeng Zhu, Qibao Zhou, Fei Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Oncology
Subjects:
acute promyelocytic leukemia
variant APL
TFG::RARA
venetoclax
all-trans retinoic acid
arsenic trioxide
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1529640/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items